/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Alzamend Neuro Inc share price today is $2, up -4.13%. The stock opened at $2.165 against the previous close of $2.18, with an intraday high of $2.165 and low of $2.06.

style

pb-0

Alzamend Neuro Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$2 -0.0413(-4.13%) ALZN at 13 Mar 2026 11:58 AM Biotechnology

Lowest Today 2.06

Highest Today 2.165

Today’s Open 2.165

Prev. Close 2.18

52 Week High 10.17

52 Week Low 1.58

Day’s Range: Low 2.06 High 2.165

52-Week Range: Low 1.58 High 10.17

Alzamend Neuro Inc Institutional Holdings

Alzamend Neuro Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Alzamend Neuro Inc Fundamentals

Market Cap 8.29 M

PB Ratio 1.8962

PE Ratio 0.0

Enterprise Value 8.22 M

Total Assets 4.60 M

Volume 44900

Alzamend Neuro Inc Company Financials

Annual Revenue FY25:0 0.0M, FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M

Annual Profit FY25:-50740 -0.1M, FY24:-50740 -0.1M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-4514853 -4.5M, FY24:-9947746 -9.9M, FY23:-14878167 -14.9M, FY22:-12404583 -12.4M, FY21:-5203664 -5.2M

Quarterly Revenue Q1/2026:null 0.0M, Q4/2025:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M

Quarterly Profit Q1/2026:null 0.0M, Q4/2025:-27685 -0.0M, Q3/2025:-27685 -0.0M, Q2/2025:-12685 -0.0M, Q1/2025:-12685 -0.0M

Quarterly Net worth Q1/2026:-2198991 -2.2M, Q4/2025:-1000758 -1.0M, Q3/2025:-2702684 -2.7M, Q2/2025:-1139445 -1.1M, Q1/2025:-1039000 -1.0M

About Alzamend Neuro Inc & investment objective

Company Information Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Organisation Biotechnology

Employees 4

Industry Biotechnology

CEO Mr. Stephan Jackman

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*